SCLC
Stories
-
Rudin et al. Report extended follow-up of tarlatamab in SCLC
The authors reported that median overall survival was 13.6 months with tarlatamab versus 8.4 months with chemotherapy, with 12-month OS rates of 55.9% versus 39.0%. Grade ≥3 treatment-related adverse events decreased over time, with no serious events after 12 months.